| Literature DB >> 23341367 |
Thierry Conroy1, Céline Gavoille, Emmanuelle Samalin, Marc Ychou, Michel Ducreux.
Abstract
In 2010, the FOLFIRINOX regimen (bolus and infusional 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) emerged as a new option in patients with metastatic pancreatic cancer and a good performance status. However, at that time, some doubts were raised regarding safety issues. Similarly, no data on FOLFIRINOX were published in patients with unresectable/locally advanced or borderline resectable pancreatic cancer. This article presents the available experience with FOLFIRINOX outside clinical trials in metastatic and locally advanced pancreatic cancer patients. The safety of the regimen in patients with biliary stents and in previously treated patients is also described. FOLFIRINOX usage in clinical practice, including modification of the regimen (omission of bolus 5-fluorouracil; FOLFOXIRI regimen), is also presented. These data suggest that a phase III randomized study is warranted to further explore the role of FOLFIRINOX in locally advanced pancreatic cancer.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23341367 DOI： 10.1007/s11912-012-0290-4
Source DB: PubMed Journal: Curr Oncol Rep ISSN： 1523-3790 Impact factor: 5.075